Design, synthesis and biological evaluation of CB1 cannabinoid receptor ligands derived from the 1,5-diarylpyrazole scaffold

References

• Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561–564.
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61–65.
   PubMed Web of Science ®Google Scholar
• Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev 2002;54:161–202.
   PubMed Web of Science ®Google Scholar
• Lange JH, Kruse CG. Recent advances in CB1 cannabinoid receptor antagonists. Curr Opin Drug Discov Dev 2004;7:498–506.
   PubMed Web of Science ®Google Scholar
• Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, Bernstein Y, Thomas KJ, Kim E, Walker JM, Nagar S, Ward SJ, Raffa RB. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism-or inverse agonism-as potential obesity treatment and other therapeutic use. J Clin Pharm Ther 2007;32:209–231.
   PubMed Web of Science ®Google Scholar
• Patel PN, Pathak R. Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Am J Health Syst Pharm 2007;64:481–489.
   PubMed Web of Science ®Google Scholar
• Lange JH, Kruse CG. Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov Today 2005;10:693–702.
   PubMed Web of Science ®Google Scholar
• Kakafika AI, Mikhailidis DP, Karagiannis A, Athyros VG. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol 2007;47:642–652.
   PubMed Web of Science ®Google Scholar
• Le Foll B, Goldberg SR. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 2005;312:875–883.
   PubMed Web of Science ®Google Scholar
• Song KS, Lee SH, Chun HJ, Kim JY, Jung ME, Ahn K, Kim SU, Kim J, Lee J. Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands. Bioorg Med Chem 2008;16:4035–4051.
   PubMed Web of Science ®Google Scholar
• Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994;350:240–244.
   PubMed Web of Science ®Google Scholar
• Carai MA, Colombo G, Gessa GL. Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci 2005;77:2339–2350.
   PubMed Web of Science ®Google Scholar
• Takahashi RN, Pamplona FA, Fernandes MS. The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze. Neurosci Lett 2005;380:270–275.
   PubMedGoogle Scholar
• Wise LE, Iredale PA, Stokes RJ, Lichtman AH. Combination of rimonabant and donepezil prolongs spatial memory duration. Neuropsychopharmacology 2007;32:1805–1812.
   PubMed Web of Science ®Google Scholar
• Benavides J, Boccio D, Henin Y, Piot-Grosjean O. U.S. Patent 7105504, 2006.
   Google Scholar
• Boström J, Berggren K, Elebring T, Greasley PJ, Wilstermann M. Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists. Bioorg Med Chem 2007;15:4077–4084.
   PubMed Web of Science ®Google Scholar
• Menozzi G, Fossa P, Cichero E, Spallarossa A, Ranise A, Mosti L. Rational design, synthesis and biological evaluation of new 1,5-diarylpyrazole derivatives as CB1 receptor antagonists, structurally related to rimonabant. Eur J Med Chem 2008;43:2627–2638.
   PubMedGoogle Scholar
• Barth F, Casellas P, Congy C, Martinez S, Rinaldi M, Anne-Archard G. U.S. Patent 5624941, 1997.
   Google Scholar
• Schweizer EE, Hayes JE, Lee KJ, Rheingold AL. Reactions of azines. 10. Synthesis of 4H, 6H-pyrazolo[1,5-c]oxazol-4-ylidenes,4H-pyrrolo[1,2-b]pyrazole-4-ones,and/or 4H, 8H-pyrazolo [1,5-c][1,3]oxazepin-4-ones. J Org Chem 1987;52:1324–1332.
   Google Scholar
• Hurst D, Umejiego U, Lynch D, Seltzman H, Hyatt S, Roche M, McAllister S, Fleischer D, Kapur A, Abood M, Shi S, Jones J, Lewis D, Reggio P. Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction. J Med Chem 2006;49:5969–5987.
   PubMed Web of Science ®Google Scholar
• Lan R, Liu Q, Fan P, Lin S, Fernando SR, McCallion D, Pertwee R, Makriyannis A. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 1999;42:769–776.
   PubMedGoogle Scholar
• Francisco ME, Seltzman HH, Gilliam AF, Mitchell RA, Rider SL, Pertwee RG, Stevenson LA, Thomas BF. Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716). J Med Chem 2002;45:2708–2719.
   PubMed Web of Science ®Google Scholar
• William V. Murray, Susan K. Hadden, Michael P. Wachter. Synthesis of 3-(1,5-diphenyl-3-pyrazolyl)aryl propanoates. J Heterocycl Chem 1990;27:1933–1940.
   Google Scholar
• Zimmer H, Amer A. Some Novel Observations on the Reaction of 1-Hydrazinophthalazine with Polycarbonyl Compounds. Heterocycles 1987;26:1177–1182.
   Web of Science ®Google Scholar